Systematic review: non-adherence and non-persistence in intravitreal treatment

被引:47
作者
Ehlken, Christoph [1 ]
Ziemssen, Focke [2 ]
Eter, Nicole [3 ]
Lanzl, Ines [4 ]
Kaymak, Hakan [5 ]
Lommatzsch, Albrecht [6 ]
Schuster, Alexander K. [7 ]
机构
[1] Univ Klinikum Schleswig Holstein, Klin Ophthalmol, Campus Kiel, Kiel, Germany
[2] Eberhard Karl Univ, Ctr Ophthalmol, Tubingen, Germany
[3] Univ Klinikum Munster, Klin Augenheilkunde, Munster, Germany
[4] Chiemsee Augen Tagesklin, Prien Am Chiemsee, Germany
[5] Makula Netzhaut Zentrum, Dusseldorf, Germany
[6] Hosp Munster, Augenzentrum St Franziskus, Munster, Germany
[7] Univ Med Mainz, Augenklin & Poliklin, Mainz, Germany
关键词
VEGF; Adherence; Persistence; AMD; DME; Intravitreal; ANTI-VEGF TREATMENT; BIMANUAL LID RETRACTION; TOPICAL LIDOCAINE GEL; GROWTH-FACTOR THERAPY; MACULAR DEGENERATION; RANIBIZUMAB TREATMENT; ANESTHETIC TECHNIQUES; PATIENT PREFERENCES; OCULAR PAIN; INJECTION;
D O I
10.1007/s00417-020-04798-2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose Intravitreal injection of VEGF inhibitors has become the standard of care for different macular diseases within the last years resulting in improved visual outcomes. Under real-life conditions, however, the necessity for frequent retreatments and reexaminations poses a burden for patients and treatment centers. Non-adherence and non-persistence to intravitreal treatment may lead to inferior clinical outcomes, and knowledge of contributing factors is crucial to improve adherence. This systematic review analyzes current literature for potential factors involved in non-adherence and non-persistence. Methods A systematic search was conducted in PubMed and Embase including three different aspects of intravitreal injection therapy: (1) diseases with intravitreal injections as treatment, (2) intravitreal injection, and (3) aspects of therapy adherence or therapy persistence. Data from identified quantitative studies were further extracted and grouped according to WHO criteria (condition, socio-economy, therapy, patient, and health system). The methodological quality of identified studies was graded. Identified qualitative studies (i.e., interviews) were descriptively analyzed and their findings narratively reported. Results Twenty-four publications were included. In 16 of those publications, a quantitative data analysis was conducted, analyzing factors associated with non-adherence. Worse visual acuity at baseline and unfavorable development of visual acuity, higher age, and greater distance to the treatment center were associated with non-adherence, while there was inconsistent evidence for an association of comorbidity. In qualitative studies, high follow-up/treatment burden, fear and anxiety, disappointed patient expectations, and lack of motivation to continue treatment were reported as reasons for non-persistence. Conclusions Knowledge of potential barriers in IVT treatment may improve adherence and potentially clinical results. Improvements can be achieved particularly in the healthcare complex (organizational improvements) and the "patient" complex by establishing realistic expectations. Recurrent education of the patient may be necessary.
引用
收藏
页码:2077 / 2090
页数:14
相关论文
共 77 条
  • [1] What is patient adherence? A terminology overview
    Ahmed, Rana
    Aslani, Parisa
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2014, 36 (01) : 4 - 7
  • [2] Patients' tolerance of bimanual lid retraction versus a metal speculum for intravitreal injections
    Alattas, Khadijah
    [J]. CLINICAL OPHTHALMOLOGY, 2016, 10 : 1719 - 1721
  • [3] [Anonymous], QUAL ASS TOOL OBS CO
  • [4] [Anonymous], 2013, Adherence to Long-Term Therapies: Evidence for Action, DOI [10.4028/www.scientific.net/AMM.321-324.1779, DOI 10.4028/WWW.SCIENTIFIC.NET/AMM.321-324.1779]
  • [5] OUTCOMES OF AN INTRAVITREAL INJECTION CLINIC
    Atchison, Elizabeth A.
    Omar, Ahmed F.
    Iezzi, Raymond
    Barkmeier, Andrew J.
    Bakri, Sophie J.
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2017, 37 (07): : 1371 - 1376
  • [6] Non-adherence to statin therapy: a major challenge for preventive cardiology
    Bates, T. R.
    Connaughton, V. M.
    Watts, G. F.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (18) : 2973 - 2985
  • [7] Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis
    Baxter, J. M.
    Fotheringham, A. J.
    Foss, A. J. E.
    [J]. EYE, 2016, 30 (05) : 698 - 704
  • [8] Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010
    Bloch, Sara Brandi
    Larsen, Michael
    Munch, Inger Christine
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2012, 153 (02) : 209 - 213
  • [9] Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting
    Boulanger-Scemama, E.
    Querques, G.
    About, F.
    Puche, N.
    Srour, M.
    Mane, V.
    Massannba, N.
    Canoui-Poitrine, F.
    Souied, E. H.
    [J]. JOURNAL FRANCAIS D OPHTALMOLOGIE, 2015, 38 (07): : 620 - 627
  • [10] Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration
    Boyle, Jessica
    Vukicevic, Meri
    Koklanis, Konstandina
    Itsiopoulos, Catherine
    Rees, Gwyneth
    [J]. PSYCHOLOGY HEALTH & MEDICINE, 2018, 23 (02) : 127 - 140